Group 1: Brand Development - The company is expanding its brand presence by targeting retail pharmacies and online platforms while reinforcing its hospital market [2] - A brand upgrade event was held on December 6, 2025, introducing the "Mr. Pain Relief" branding to enhance market competitiveness [2] - The new slogan "For pain relief, choose Jiudian" aims to address consumer pain points and improve brand recognition [2] Group 2: Financial Performance and Market Strategy - The implementation of centralized procurement for the Loxoprofen Sodium Gel Patch may lead to a temporary decline in gross margin due to price adjustments [3] - In 2026, the company plans to stabilize existing business while driving innovation, focusing on both hospital and retail markets [3] - The company has 18 products eligible for continued procurement under national centralized purchasing agreements, which will support sales and market expansion [3] Group 3: Product Development and Innovation - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of 2026 and initiate Phase II trials [4] - The company has established a clear and competitive matrix of external products, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, with significant advantages in exclusivity and insurance coverage [4] - The company aims to enhance its product offerings to meet diverse clinical and consumer needs, particularly in the traditional plaster market [4] Group 4: Employee Incentives and Corporate Governance - The completed share repurchase plan will primarily be used for employee stock incentives to align interests between the company, shareholders, and core team [4] - Future stock incentive plans will be developed based on market conditions and strategic planning to motivate employees and foster talent [4]

Core Viewpoint - The company, Jiudian Pharmaceutical, has won the bid for its core product, Loxoprofen Sodium Gel Patch, at the lowest price in the 11th national centralized procurement, which may pressure its gross margin in the short term, necessitating an increase in sales to cope with market competition [1] Business Strategy - The company has set a strategic goal for 2026 to drive growth through a dual approach of "stabilizing the existing business base and innovative transformation," ensuring sales of centralized procurement products in hospitals while expanding OTC channels and strengthening brand presence, as well as advancing the pipeline for innovative drug development [2] Product Development Progress - In the field of external preparations, the innovative drug JIJ02 gel is currently in the clinical stage, while the traditional Chinese medicine product, Jiao Qi Pain Relief Gel Patch, has been submitted for production approval. Unique products such as Ketoprofen Gel Patch and Daiwen Moxibustion Patch are prioritized for promotion [3] Company Status - The company plans to evaluate high-quality products or assets based on strategic needs and does not rule out acquisitions to enrich its product line. Additionally, it aims to establish a sustainable shareholder return plan based on operational performance and cash flow over the next 2-3 years [4]

Group 1: Company Overview - The company is Hunan Jiutian Pharmaceutical Co., Ltd., with stock code 300705 and bond code 123223 [1][2]. Group 2: Innovation and Product Development - The company is developing innovative external preparations, including the acne treatment JIJ02 gel, which is currently in clinical development [2]. - In the traditional Chinese medicine sector, the company has submitted production applications for the pepper pain relief gel patch and has received clinical trial approval for JIZM01 and JIZM02 [2][3]. - The company employs a dual approach of independent research and project introduction to enhance its innovative drug pipeline [2][4]. Group 3: Strategic Focus for 2026 - In 2026, the company aims to stabilize its existing business while driving innovation through a dual strategy [4]. - Key initiatives include promoting the sales of existing products like the Loxoprofen Sodium Gel Patch and enhancing brand recognition through the new "Jiutian Pain Relief Mr." branding [4]. - The company plans to expand into high-end pharmaceutical excipients while adhering to GMP management policies [4]. Group 4: Market Performance and Strategies - Despite a sluggish external market, the company has maintained stable growth in its external market by leveraging a professional OTC team of over 200 members [5]. - The company focuses on brand-driven strategies and patient education to enhance brand recognition and consumer loyalty [5]. - The integrated supply chain of "formulations + raw materials + pharmaceutical excipients" provides quality assurance and cost competitiveness [5]. Group 5: Acquisition Strategy - The company is open to evaluating and acquiring high-quality products or assets that align with its strategic development needs [7]. Group 6: Product Matrix - The company has established a clear and advantageous external product matrix, including products like Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, which have significant competitive advantages [7]. - The Ketoprofen Gel Patch is a key exclusive product under medical insurance, while the traditional Chinese medicine sector features unique products like the Strong Waist and Bone Strengthening Patch [7].

Group 1 - Zhongchong Co., Ltd. plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 78 yuan per share for the purpose of convertible bond conversion [1] - Dafu Technology intends to apply for the issuance of no more than 300 million yuan in corporate bonds to meet operational needs, including debt repayment and project construction [2] - Guoyao Yizhi expects a net profit of 1.055 billion to 1.215 billion yuan in 2025, representing a year-on-year increase of 64.20% to 89.11% [3] Group 2 - Huada Zhizao anticipates a net loss of 221 million to 273 million yuan in 2025, with a reduction in losses compared to the previous year [4] - Aokema forecasts a net loss of approximately 170 million to 220 million yuan for 2025, compared to a loss of 48.53 million yuan in the previous year [5] - Zhaojin Gold expects a net profit of 122 million to 182 million yuan in 2025, recovering from a loss of 127 million yuan in the previous year [6] Group 3 - Fangsheng Pharmaceutical's subsidiary has received a drug registration certificate for a pain relief gel, which is now approved for production [7] - Weichai Heavy Machinery clarifies that it does not have gas medium-speed engine products entering the North American power generation market, countering recent rumors [8] - Hunan Gold plans to acquire 100% equity of Jintian Yue and Zhongnan Smelting through share issuance, enhancing resource control and profitability [9][10] Group 4 - Hunan Gold expects a net profit of 1.27 billion to 1.608 billion yuan in 2025, with a year-on-year increase of 50% to 90% [11] - Juchip Technology anticipates a net profit of approximately 204 million yuan in 2025, reflecting a year-on-year increase of 91.40% [12] - Huangshan Gujie forecasts a net profit of 51 million to 61 million yuan in 2025, representing a decline of 45.50% to 54.43% [13] Group 5 - Sitwei expects a net profit of 976 million to 1.031 billion yuan in 2025, with a year-on-year increase of 149% to 162% [14] - Zhongwei Semiconductor anticipates a net profit of approximately 284 million yuan in 2025, reflecting a year-on-year increase of 107.55% [16] - Xiandao Intelligent expects a net profit of 1.5 billion to 1.8 billion yuan in 2025, with a significant year-on-year increase of 424.29% to 529.15% [17] Group 6 - Huadong Heavy Machinery has received a bid notification from Adani Group for smart port equipment projects, with a total project value of approximately 1.25 billion yuan [18] - Haimuxing anticipates a net loss of 850 million to 910 million yuan in 2025, compared to a loss of 163 million yuan in the previous year [19] - Fuda Co., Ltd. expects a net profit of 310 million to 330 million yuan in 2025, with a year-on-year increase of 67.31% to 78.11% [20][21] Group 7 - Andar Intelligent forecasts a net loss of 100 million to 140 million yuan in 2025, compared to a loss of 30.74 million yuan in the previous year [22] - Zhengzhou Coal and Electricity expects a net loss of approximately 916 million yuan in 2025, compared to a profit of 283 million yuan in the previous year [23] - Bayi Steel anticipates a net loss of 1.85 billion to 2.05 billion yuan in 2025, compared to a loss of 1.75 billion yuan in the previous year [24] Group 8 - Zhichun Technology expects a net loss of 300 million to 450 million yuan in 2025, compared to a profit of 23.6 million yuan in the previous year [25] - Xindian Software forecasts a net profit of 26.4 million to 39.6 million yuan in 2025, representing a decline of 80.61% to 87.08% [26] - CIMC Vehicles is involved in a U.S. anti-subsidy and anti-dumping investigation regarding trailers and subassemblies from Mexico, Canada, and China [27] Group 9 - Aidi Pharmaceutical anticipates a net loss of approximately 16 million to 24 million yuan in 2025, with increased sales expenses impacting profitability [28] - Changjiu Logistics expects a net loss of 50 million to 75 million yuan in 2025, compared to a profit of 79.56 million yuan in the previous year [29] - Hefei China forecasts a net loss of 25 million to 36 million yuan in 2025, with challenges arising from industry policy adjustments [30][31] Group 10 - Zhongcheng Co., Ltd. has received approval from the Shenzhen Stock Exchange for a share issuance to acquire 100% equity of a clean energy company [32] - Xinbang Pharmaceutical needs to pay back taxes and penalties totaling 50.79 million yuan, which will impact its 2025 financial results [33] - Lier Technology reports a net profit of 42.46 million yuan in 2025, with a year-on-year increase of 13.67% [34] Group 11 - Delijia plans to invest 5 billion yuan in a research and manufacturing project for wind turbine gearboxes [35] - Yongjie New Materials intends to purchase 100% equity of a company for approximately 1.8 million USD in cash [36] - Yuyuan Co., Ltd. expects to report a loss for the 2025 fiscal year [37] Group 12 - Luoyang Molybdenum has completed the acquisition of gold mining projects, with total gold resources of 5.013 million ounces [38]

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].

Stock Trading Volatility - Fenglong Co., Ltd. will conduct a review of stock trading volatility due to a 405.74% price increase over 17 consecutive trading days, resulting in a trading suspension starting January 26, 2026, for up to 5 trading days [2] - Jiamei Packaging has experienced a 408.11% price increase from December 17, 2025, to January 23, 2026, leading to a similar trading suspension starting January 26, 2026, for up to 5 trading days [3] Market Uncertainty - Hunan Silver has reported significant stock price fluctuations, indicating a high risk of speculation, with its price deviating from market trends. The future market price of silver products remains uncertain due to recent increases in international silver prices [4] Corporate Transactions - Yongjie New Materials plans to acquire 100% equity of Aokening Qinhuangdao and 95% equity of Aokening Kunshan for a total consideration of approximately 1.8 billion USD [5] - Zhongcheng Co., Ltd. has received approval from the Shenzhen Stock Exchange for a share issuance to acquire 100% equity of Jiangsu Clean Energy Co., Ltd. from China Technical Import and Export Corporation, pending further regulatory approval [8] Financial Performance Forecasts - XianDao Intelligent expects a net profit of 1.5 billion to 1.8 billion CNY for 2025, representing a year-on-year increase of 424.29% to 529.15% due to a recovery in the global power battery market [10] - Zhongwei Semiconductor anticipates a net profit of approximately 284 million CNY for 2025, reflecting a growth of about 107.55% [10] - Lier Technology forecasts a net profit increase of 13.67% for 2025, driven by significant growth in its carbon foil business [11] - Yuxin Technology expects a net profit of 204 million CNY for 2025, marking a 91.4% increase due to strong demand for AI-related products [11] Share Buyback and Repurchase - Zhongchong Co., Ltd. plans to repurchase shares worth 100 million to 200 million CNY for convertible bond conversion purposes, with a maximum buyback price of 78 CNY per share [16] Resumption of Trading - Hunan Gold will resume trading on January 26, 2026, after announcing plans to acquire 100% equity of Golden Tianyue and Zhongnan Smelting, enhancing its control over gold mining resources and refining processes [17]

Core Viewpoint - Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., received the drug registration certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration, indicating a significant regulatory approval for a new product aimed at treating osteoarthritis pain and inflammation [1] Group 1 - The product, Loxoprofen Sodium Gel Patch, is specified to contain 100 mg of Loxoprofen Sodium per patch, with dimensions of 14 cm x 10 cm and a total gel weight of 10 g [1] - The drug has been approved under the national drug approval number H20263068 and does not require consistency evaluation, which may streamline its market entry [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the production of Loxoprofen Sodium Gel Patch, which is now approved for manufacturing [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after trauma, providing anti-inflammatory and analgesic effects [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid class, known for its significant analgesic effects [1] - The product is developed by LEADCHEMICAL CO., LTD. and is one of the leading analgesic drugs in the Chinese market in terms of long-term sales [1] Group 2: Mechanism of Action - The mechanism of action involves the inhibition of prostaglandin synthesis through the suppression of cyclooxygenase [1] - Loxoprofen Sodium acts as a prodrug, which is converted into its active metabolite trans-OH after transdermal absorption [1]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the production of Loxoprofen Sodium Gel Patch, marking a significant milestone in the company's product portfolio [1] Group 1 - The drug registration certificate for Loxoprofen Sodium Gel Patch was issued on January 23, 2026, allowing for production [1] - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, indicating a competitive market landscape [1] - Among the registered companies, listed firms include Jiutian Pharmaceutical (300705), Darentang (600329), and China Resources Sanjiu (000999), while the remaining manufacturers are non-listed [1]